The FDA is revising the labels of Abbott Laboratories' Norvir and Genentech's Invirase to include a warning about the risk of abnormal heart rhythm when the HIV drugs are taken together. Separately, European regulators reviewed data on the risk and advised patients to take a low-dose Invirase for a week initially, as a precautionary measure.

Full Story:

Related Summaries